Contemporary OB/GYN week in review: Ovaprene, menopause visit, and more
Review some of the top stories from the Contemporary OB/GYN website over the last week, and catch up on anything you may have missed.
Contemporary OB/GYN week in review: Ovaprene, menopause visit, and more
Thank you for visiting the Contemporary OB/GYN® website. Take a look at some of our top stories from last week (Monday, April 08 - Friday, April 12 2024), and click each link to read and watch anything you may have missed.
1.) Ovaprene indicated effective for non-hormonal contraception
A comprehensive investigation confirmed Ovaprene's non-hormonal design achieves consistent contraceptive efficacy, paving the way for further pivotal trials in pregnancy risk assessment.
Click here for the full article.
2.) Maximizing your menopause health care visit
Learn how to prepare for your menopause healthcare visit effectively and make the most out of your time with health care professionals, as advised by experts selected by The Menopause Society.
Click here for the full article.
3.) Trends in STI prevalence and testing guidelines
In a recent interview, Cheruba Prabakar, MD, FACOG, shed light on the rising prevalence of sexually transmitted infections in the United States and the need for improved awareness and testing, particularly for overlooked conditions such as trichomoniasis.
Click here for the full article.
4.) Adverse impacts of vulvovaginal atrophy found for quality of life
Learn about the symptoms of vulvovaginal atrophy and their frequency and impact in postmenopausal women, leading to extreme discomfort in some cases.
Click here for the full article.
5.) Does acetaminophen intake during pregnancy influence children’s risk of neurodevelopmental disorders?
A recently published study in JAMA sought to determine if there is a link between acetaminophen use during pregnancy and children’s risk of developing autism, ADHD, or intellectual disabilities.
S4E3: Myfembree for moderate-to-severe endometriosis pain: Potential for adolescents
March 2nd 2022In this episode of Pap Talk, Contemporary OB/GYN® Associate Editor Lindsey Carr sat down with Jessica Shim, MD, an attending at in the Division of Gynecology, Department of Surgery, Boston Children’s Hospital; Harvard Medical School Boston, Massachusetts, to discuss Myfembree (relugolix, estradiol, and norethindrone acetate tablets; Myovant Sciences, Pfizer) and its possible approval in May 2022.
Listen
No link found between antenatal corticosteroids and child neurodevelopment
April 25th 2024A recent study found no link between antenatal corticosteroid administration and adverse neurodevelopmental outcomes in children aged 6 years or older, offering reassurance for late preterm delivery practices.
Read More
S4E1: New RNA platform can predict pregnancy complications
February 11th 2022In this episode of Pap Talk, Contemporary OB/GYN® sat down with Maneesh Jain, CEO of Mirvie, and Michal Elovitz, MD, chief medical advisor at Mirvie, a new RNA platform that is able to predict pregnancy complications by revealing the biology of each pregnancy. They discussed recently published data regarding the platform's ability to predict preeclampsia and preterm birth.
Listen
Hormone therapy safety: Study finds potential benefits for senior women
April 24th 2024A recent large-scale study challenged age-related concerns, suggesting hormone therapy may offer safety and even benefits for menopausal women aged over 65 years, aligning with The Menopause Society's 2022 Position Statement.
Read More
Hyperoxygenation use not linked to neonatal outcomes
April 23rd 2024Recent research evaluated the impact of maternal hyperoxygenation on neonatal Apgar scores, revealing no significant enhancement in outcomes among women with pathologic fetal heart rate tracing and suggesting limited efficacy of hyperoxygenation therapy in this context.
Read More
